| Datum | Zeit | Quelle | Überschrift | Symbol | Firma |
| 04/03/2025 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 25/02/2025 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 14/02/2025 | 06h15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 12/02/2025 | 17h38 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 12/02/2025 | 17h38 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 12/02/2025 | 17h38 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 12/02/2025 | 15h22 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 12/02/2025 | 06h15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 05/02/2025 | 22h17 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 05/02/2025 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 31/01/2025 | 22h15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 22/01/2025 | 23h01 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 14/01/2025 | 22h15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 13/01/2025 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 08/01/2025 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 02/01/2025 | 06h15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 23/12/2024 | 22h52 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 06/12/2024 | 22h36 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 22/11/2024 | 22h48 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 22/11/2024 | 22h23 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 22/11/2024 | 14h36 | GlobeNewswire Inc. | Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 12/11/2024 | 14h04 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 12/11/2024 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 11/11/2024 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 07/11/2024 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 23/10/2024 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics to Present at Two Upcoming Investor Conferences | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 22/10/2024 | 14h05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 22/10/2024 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 15/10/2024 | 14h00 | GlobeNewswire Inc. | Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data | NASDAQ:INDP | Indaptus Therapeutics Inc |
| 10/10/2024 | 22h05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:INDP | Indaptus Therapeutics Inc |
